Aducanumab Submitted in Japan, but Decision Unlikely to Come Until Next Autumn

Biogen’s controversial Alzheimer’s treatment aducanumab has been finally submitted for approval in Japan, but with the drug subject to standard review, a regulatory decision would not be made until next autumn or winter. If it comes at the end of...read more